123 related articles for article (PubMed ID: 7808670)
1. [Effectiveness of quarterly assessment of CEA, TPA and GICA serum levels in gastric and colorectal carcinomas: Prospective study of 174 patients undergoing radical surgery].
Barillari P; Ricci M; Broglia S; Manetti G; Cerasi A; Cesareo S; Calcaterra D; Cioè I; Caronna R; Sammartino P
Minerva Chir; 1994 Oct; 49(10):953-61. PubMed ID: 7808670
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
3. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
Barillari P; Sammartino P; Cardi M; Ricci M; Gozzo P; Cesareo S; Cerasi A
Aust N Z J Surg; 1991 Sep; 61(9):675-80. PubMed ID: 1877936
[TBL] [Abstract][Full Text] [Related]
5. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
7. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
[TBL] [Abstract][Full Text] [Related]
9. The miniscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer.
Wolf RF; Cohen AM
J Am Coll Surg; 1997 Jul; 185(1):60-4. PubMed ID: 9208962
[TBL] [Abstract][Full Text] [Related]
10. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Grotowski M
Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
[TBL] [Abstract][Full Text] [Related]
11. [CEA, GICA, TPA, fibrinopeptide-A, gamma-GT and gastric cancer. A contribution to the rationalization of a combined assay].
Abbasciano V; Graziano L; Arcudi D; Tassinari D; Nielsen I; Sartori S
Recenti Prog Med; 1991 Oct; 82(10):517-9. PubMed ID: 1684676
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
13. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin.
Chan AO; Chu KM; Lam SK; Cheung KL; Law S; Kwok KF; Wong WM; Yuen MF; Wong BC
Cancer; 2005 Aug; 104(4):740-6. PubMed ID: 15991243
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal cancer].
Takahashi Y
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer.
Wichmann MW; Lau-Werner U; Müller C; Hornung HM; Stieber P; Schildberg FW;
Anticancer Res; 2000; 20(6D):4953-5. PubMed ID: 11326645
[TBL] [Abstract][Full Text] [Related]
19. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
20. Value of follow-up in the management of recurrent colorectal cancer.
Camuñas J; Enriquez JM; Devesa JM; Morales V; Millan I
Eur J Surg Oncol; 1991 Oct; 17(5):530-5. PubMed ID: 1936302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
